AIM2 and malignant colon neoplasm: AIM2 was originally regarded as a tumour suppressor because its inactivation or mutation was found in a variety of tumours, including endometrial, gastric, and colon cancers, but it was found to be overexpressed in oral, nasopharyngeal, and non-small-cell lung cancer22.